As of May, 2 Analysts See $-0.25 EPS for Veracyte, Inc. (VCYT)

April 20, 2018 - By Robert Judd

Veracyte, Inc. (NASDAQ:VCYT) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.23. That’s change of 0.53, from 2017Q3’s 1.76. 15 investors sold all, 16 reduced holdings as Veracyte, Inc. ratio is negative. 26 rose positions while 12 funds acquired positions. Funds hold 21.45 million shares thus 4.52% less from 2017Q3’s 22.46 million shares.
Venbio Select Advisor Limited Liability holds 0.32% or 752,455 shs in its capital. California-based Schwab Charles Invest Management Inc has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Quantum holds 86,963 shs or 0.14% of its capital. State Of Wisconsin Investment Board holds 0% or 17,000 shs in its capital. Us-based Grandeur Peak Glob Advsrs Ltd Company has invested 0.28% in Veracyte, Inc. (NASDAQ:VCYT). California State Teachers Retirement Systems holds 0% or 37,021 shs. Barclays Public Ltd Liability Corp holds 0% in Veracyte, Inc. (NASDAQ:VCYT) or 3,758 shs. Janney Montgomery Scott Limited Liability Co reported 11,100 shs. Ny State Common Retirement Fund accumulated 25,200 shs or 0% of the stock. Morgan Stanley reported 164,565 shs. 34,500 were reported by Spark Invest Mngmt Ltd. International Gp Incorporated invested in 15,955 shs or 0% of the stock. Millennium Mgmt Ltd reported 780,770 shs. Jpmorgan Chase owns 5,110 shs for 0% of their capital. Moreover, Meeder Asset Management has 0% invested in Veracyte, Inc. (NASDAQ:VCYT).

On May, 2 WallStreet awaited Veracyte, Inc. (NASDAQ:VCYT)’s earnings report, RTT reports. The earnings per share diference is $0.01 or 4.17 % down from last years number. Previous year: $-0.24; Analysts forcast: $-0.25. Analysts at Wall Street see Veracyte, Inc.’s 4.17 % negative EPS growth compared to $-0.24 earnings per share for last quarter. Ticker’s shares touched $5.82 during the last trading session after 0.95% change.Currently Veracyte, Inc. is downtrending after 39.30% change in last April 20, 2017. VCYT has 17,032 shares volume. VCYT underperformed by 50.85% the S&P500.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

A total of 3 analysts rate Veracyte (NASDAQ:VCYT) as follows: 1 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 33% are bullish. (NASDAQ:VCYT) has 4 ratings reports on Apr 20, 2018 according to StockzIntelligence. On Tuesday, November 7 the firm earned “Hold” rating by Piper Jaffray. On Tuesday, November 7 the stock of Veracyte, Inc. (NASDAQ:VCYT) has “Outperform” rating given by Leerink Swann. On Tuesday, November 7 the stock of Veracyte, Inc. (NASDAQ:VCYT) has “Neutral” rating given by Janney Capital. In Wednesday, April 18 report Piper Jaffray maintained the stock with “Hold” rating.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States.The company has $199.74 million market cap. The firm uses genomic technology to resolve diagnostic ambiguity.Last it reported negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: